ARC1779

DRUG3 trials

Sponsors

Archemix Corp.

Conditions

Purpura, Thrombotic ThrombocytopenicThrombosisVon Willebrand DiseaseVon Willebrand Disease Type-2b

Phase 1

Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 in Healthy Volunteers

CompletedNCT00432770

Archemix Corp.Thrombosis

Start: 2006-12-31End: 2007-03-31Target: 42Updated: 2007-04-20

Phase 2

ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders

CompletedNCT00632242

Archemix Corp.Purpura, Thrombotic Thrombocytopenic, Von Willebrand Disease Type-2b

Start: 2008-01-31End: 2008-12-31Target: 28Updated: 2009-01-09

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B

WithdrawnNCT00694785

Archemix Corp.Von Willebrand Disease

Start: 2008-10-31Target: 2Updated: 2009-08-21